Compound profile
Bremelanotide
Stronger clinical signalAlso known as: PT-141 · Vyleesi
A melanocortin-receptor agonist derived from Melanotan II research, FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Notable as one of the only peptides in this category with a formal drug approval.
Overview
Bremelanotide, known during its research years by the code name PT-141, is a cyclic peptide that activates melanocortin receptors in the central nervous system. It traces its origin to research at the University of Arizona in the 1980s, where Mac Hadley and Victor Hruby were studying analogues of alpha-melanocyte-stimulating hormone, or alpha-MSH, initially with the goal of understanding pigmentation and skin cancer prevention rather than sexual desire.
That work produced Melanotan II first, a broader acting melanocortin agonist. During early human testing of Melanotan II, researchers noticed it reliably produced erections and increased self-reported sexual desire in male subjects, an unexpected finding that redirected part of the research program toward the melanocortin system as a treatment target for sexual dysfunction. Bremelanotide was developed from that work as a smaller, more selective heptapeptide, structurally described as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, engineered to favor the melanocortin receptor subtypes involved in desire and arousal over the receptor responsible for skin pigmentation.
Bremelanotide is one of the few peptides in this category that is a genuinely approved prescription drug rather than a research chemical. Palatin Technologies developed it into Vyleesi, which the FDA approved on June 21, 2019, for hypoactive sexual desire disorder, or HSDD, in premenopausal women, making it the first FDA-approved medicine that works through the central nervous system specifically to increase sexual desire, distinct from erectile dysfunction drugs that act on blood flow in the genitals.
Mechanism (plain language)
Non-selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, acting on desire and arousal pathways rather than on genital blood flow directly, distinguishing it mechanistically from PDE5-inhibitor erectile-dysfunction drugs.
How it works
Bremelanotide acts on melanocortin receptors, a family of receptors involved in a range of processes including pigmentation, energy balance, and sexual function, depending on which receptor subtype and which part of the body is involved. It engages these receptors non-selectively but is understood to act mainly through MC3R and MC4R in the central nervous system, receptors concentrated in brain regions involved in sexual arousal and desire, rather than through MC1R, which governs skin pigmentation and is the receptor most active with Melanotan II.
Because it works centrally, in the brain and nervous system, rather than on blood vessels or genital tissue directly, bremelanotide's mechanism is fundamentally different from PDE5 inhibitor drugs like sildenafil, which act locally to increase blood flow. Bremelanotide is intended to influence the brain's desire and arousal circuitry itself, which is why it is approved specifically for a desire disorder rather than for erectile or arousal difficulties rooted in blood flow, and why it is dosed as needed before anticipated sexual activity rather than daily.
What research suggests
Two identically designed phase 3 RCTs (the RECONNECT trials) in premenopausal women with HSDD reported statistically significant increases in sexual desire and reductions in related distress versus placebo, supporting FDA approval.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Increased sexual desire
Two identically designed phase 3 trials, known as the RECONNECT studies, in premenopausal women with HSDD reported statistically significant increases in sexual desire scores compared with placebo, the basis for FDA approval.
Reduced distress related to low desire
The same RECONNECT trials reported reductions in the distress associated with low sexual desire, a co-primary endpoint alongside the desire score itself.
Central nervous system mechanism distinct from vascular drugs
Its mechanism of action, working through brain melanocortin receptors rather than local blood flow, offers an option distinct from PDE5 inhibitors for people whose difficulty is rooted in desire rather than genital blood flow.
As-needed dosing schedule
The approved label allows dosing shortly before anticipated sexual activity rather than continuous daily use, which trial data supported as an effective administration pattern.
Uncertainties & risks
Approved specifically for HSDD in premenopausal women, on an as-needed dosing schedule set by the label, not a general-purpose libido or performance product. Nausea, flushing, and headache are common; clinical benefit size has been debated as modest despite statistical significance.
Bremelanotide is approved specifically for hypoactive sexual desire disorder in premenopausal women, using the dosing schedule set out in its FDA label, and it is not a general-purpose libido or sexual performance product for other populations, despite how it is sometimes discussed online alongside unapproved research peptides. Its approval was based on statistically significant trial results, but reviewers and some independent commentators have described the absolute clinical benefit as modest, meaning the average improvement, while real, was not large in absolute terms. Nausea is the most common side effect, reported in a substantial share of trial participants, along with flushing, headache, and injection site reactions, and nausea rates were high enough that they factored into ongoing label and dosing discussions. Because it shares mechanistic ancestry with Melanotan II, it is sometimes discussed in the same conversations as that unapproved tanning peptide, but the two are chemically distinct compounds with very different regulatory status, and bremelanotide is the one that went through full clinical trials and FDA review, not Melanotan II.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.